EE9900587A - CD154 blokaadravi terapeutilise valgu inhibiitorsündroomi puhul - Google Patents

CD154 blokaadravi terapeutilise valgu inhibiitorsündroomi puhul

Info

Publication number
EE9900587A
EE9900587A EEP199900587A EEP9900587A EE9900587A EE 9900587 A EE9900587 A EE 9900587A EE P199900587 A EEP199900587 A EE P199900587A EE P9900587 A EEP9900587 A EE P9900587A EE 9900587 A EE9900587 A EE 9900587A
Authority
EE
Estonia
Prior art keywords
blockade
protein inhibitor
therapeutic protein
exogenous protein
inhibitor syndrome
Prior art date
Application number
EEP199900587A
Other languages
English (en)
Estonian (et)
Inventor
Adelman Burt
Original Assignee
Biogen, Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Incorporated filed Critical Biogen, Incorporated
Publication of EE9900587A publication Critical patent/EE9900587A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
EEP199900587A 1997-06-20 1998-06-19 CD154 blokaadravi terapeutilise valgu inhibiitorsündroomi puhul EE9900587A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5027697P 1997-06-20 1997-06-20
PCT/US1998/012773 WO1998058672A1 (en) 1997-06-20 1998-06-19 Cd154 blockade therapy for therapeutic protein inhibitor syndrome

Publications (1)

Publication Number Publication Date
EE9900587A true EE9900587A (et) 2000-08-15

Family

ID=21964347

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP199900587A EE9900587A (et) 1997-06-20 1998-06-19 CD154 blokaadravi terapeutilise valgu inhibiitorsündroomi puhul

Country Status (25)

Country Link
US (1) US20020119151A1 (is)
EP (1) EP1034001B1 (is)
JP (1) JP2002504910A (is)
KR (1) KR100567998B1 (is)
CN (2) CN1651071A (is)
AT (1) ATE272408T1 (is)
AU (1) AU733062B2 (is)
BG (1) BG64436B1 (is)
BR (1) BR9810755A (is)
CA (1) CA2294138A1 (is)
CZ (1) CZ295805B6 (is)
DE (1) DE69825473T2 (is)
EA (1) EA002512B1 (is)
EE (1) EE9900587A (is)
ES (1) ES2226152T3 (is)
HK (1) HK1031825A1 (is)
HU (1) HUP0002048A3 (is)
IL (1) IL133305A0 (is)
IS (1) IS2097B (is)
NO (1) NO996274L (is)
NZ (1) NZ502051A (is)
PT (1) PT1034001E (is)
SK (1) SK285962B6 (is)
TR (1) TR199903141T2 (is)
WO (1) WO1998058672A1 (is)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA005236B1 (ru) * 1998-09-21 2004-12-30 ДЖИНЕТИКС ИНСТИТЬЮТ, эЛэЛСи Композиция для лечения и/или предупреждения нарушений, приводящих к аномальному кровотечению, и способ лечения таких нарушений (варианты)
AU2001251612A1 (en) 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
CA2408691A1 (en) 2000-05-12 2001-11-22 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
IES20030299A2 (en) * 2002-04-23 2003-10-29 R Stephen Porter Inhibition of platelet aggregation
ES2353222T3 (es) * 2003-06-13 2011-02-28 Biogen Idec Ma Inc. Anticuerpos anti-cd154 (ligando cd40) aglicosilados y usos de los mismos.
AU2011224032B2 (en) * 2003-06-13 2013-01-31 Biogen Ma Inc. Aglycosyl Anti-CD154 (CD40 Ligand) Antibodies and Uses Thereof
EP1639014B1 (en) * 2003-06-13 2010-09-22 Biogen Idec MA Inc. Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
JP4765039B2 (ja) 2003-11-04 2011-09-07 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｃｄ４０抗原を発現する癌に対する治療方法。
MX2007001015A (es) 2004-07-26 2007-04-12 Biogen Idec Inc Anticuerpos anti-cd154.
WO2006017574A1 (en) * 2004-08-03 2006-02-16 Mayo Foundation For Medical Education And Research Improving treatments
WO2006125117A2 (en) 2005-05-18 2006-11-23 Novartis Ag Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
NZ571757A (en) 2006-04-21 2012-01-12 Novartis Ag Antagonist anti-CD40 antibody pharmaceutical compositions comprising arginine-HCl and a citrate or citric acid buffer
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
US9447156B2 (en) 2011-05-17 2016-09-20 St. Jude Children's Research Hospital Methods and compositions for inhibiting neddylation of proteins
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
ZA946765B (en) * 1993-09-02 1996-02-15 Dartmouth College Methods of prolonged suppression of humoral immunity
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
KR100632846B1 (ko) * 1997-01-10 2006-10-16 바이오겐 아이덱 엠에이 인코포레이티드 치료를 위한 항ｃｄ40ｌ 화합물의 투여 방법

Also Published As

Publication number Publication date
EP1034001B1 (en) 2004-08-04
HK1031825A1 (en) 2001-06-29
US20020119151A1 (en) 2002-08-29
KR100567998B1 (ko) 2006-04-07
DE69825473T2 (de) 2005-08-04
IS2097B (is) 2006-04-12
CN1651071A (zh) 2005-08-10
CA2294138A1 (en) 1998-12-30
BG64436B1 (en) 2005-02-28
AU8153698A (en) 1999-01-04
JP2002504910A (ja) 2002-02-12
SK285962B6 (sk) 2007-12-06
AU733062B2 (en) 2001-05-03
ATE272408T1 (de) 2004-08-15
NZ502051A (en) 2001-04-27
TR199903141T2 (xx) 2000-09-21
WO1998058672A1 (en) 1998-12-30
IL133305A0 (en) 2001-04-30
NO996274D0 (no) 1999-12-17
PT1034001E (pt) 2004-12-31
CZ458899A3 (cs) 2000-04-12
CZ295805B6 (cs) 2005-11-16
KR20010013964A (ko) 2001-02-26
EA200000059A1 (ru) 2000-08-28
HUP0002048A2 (hu) 2000-10-28
HUP0002048A3 (en) 2002-09-30
ES2226152T3 (es) 2005-03-16
BR9810755A (pt) 2000-08-15
EP1034001A1 (en) 2000-09-13
SK180399A3 (en) 2000-06-12
CN1261285A (zh) 2000-07-26
NO996274L (no) 2000-02-18
EA002512B1 (ru) 2002-06-27
DE69825473D1 (de) 2004-09-09
BG104092A (en) 2000-10-31
IS5274A (is) 1999-11-26

Similar Documents

Publication Publication Date Title
EE9900587A (et) CD154 blokaadravi terapeutilise valgu inhibiitorsündroomi puhul
MXPA02012443A (es) Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos.
NO953093D0 (no) Forbindelser med både sterk kalsiumantagonist- og antioksidantvirkning, samt anvendelse derav som cellebeskyttende midler
DK0782445T3 (da) Kombination af en opioidantagonist og en selektiv serotoningenoptagelsesinhibitor til behandling af alkoholisme og alkoholafhængighed
SE9800836D0 (sv) New Compounds
WO2001024816A3 (en) Compositions and methods relating to the inhibition of casomorphin and gluteomorphin
MXPA03002477A (es) N-acilsulfonamidas promotras de la apoptosis.
WO2004030627A3 (en) Synergistic methods and compositions for treating cancer
DK0719154T3 (da) Aktiveret faktor VIII som terapeutisk middel og metode til behandling af faktor VIII-mangel
MXPA00010070A (es) Mejora de respuestas inmunes medidas de proteina de fusion anticuerpo-citoquina por co-administracion con inhibidor de angiogenesis.
IS5247A (is) Notkun CD40:CD154 bindingarrofa til að koma í vegfyrir ónæmissvörun gegn aðlögun, einkum höfnun græðlinga
DK641589D0 (da) N-aryl-azetidinoner, fremgangsmaade til deres fremstilling og deres anvendelse som elastaseinhibitorer
DK1427409T3 (da) Fremgangsmåde til behandling eller forhindring af vaskulær inflammation under brug af en eller flere sterolabssorptionsinhibitorer
EA200100732A1 (ru) Противовоспалительные и иммуносупрессорные соединения, ингибирующие клеточную адгезию
DK0936902T3 (da) Spraytørrede mikropartikler som terapeutiske bærere til anvendelse i terapi
NO984760L (no) Anvendelse av en osmolytt ved behandling av effekter forÕrsaket av en infeksjon, en inflammasjon eller en immundysfunksjon
AR026901A1 (es) Peptidos con n-alquilacion que tienen actividad antiangiogenica
HK1045456A1 (en) Novel therapeutic use of viral inflammation modulatory protein in blocking xenograft rejection
BR0111785A (pt) Composições e métodos para tratamento de candidìase
WO2003099212A3 (en) Mitogen activated protein kinase inhibitor compositions for lymphoma therapy
IL111804A0 (en) Pharmaceutical compositions comprising dimeticone for the treatment of constipation
EP1009421A4 (en) PROCESS AND COMPOSITIONS FOR IMPROVED Wounds Healing
UA94022C2 (ru) Применение ингибитора il-18 для лечения и/или предупреждения алкогольного гепатита
AU2000265105A1 (en) Methods and compositions for the prevention and treatment of syndrome x
ATE255594T1 (de) Hepatitis b inhibitoren

Legal Events

Date Code Title Description
HC1A Change of owner name